LATEST RESEARCH UPDATE: A systematic review and meta-analysis of double-blind, randomized controlled trials found that PEA significantly reduces chronic pain intensity. Pooled analysis showed that PEA reduced chronic pain by 1.68 (1.05–2.31, p = 0.00001) points on a standardized 11-point pain intensity scale. All but two studies showed significant analgesic benefits of PEA. Studies included patients with chronic pain from gynecological conditions, neurological diseases, musculoskeletal disorders, and irritable bowel syndrome. Studies also showed other PEA benefits including: increased quality of life, improved sleep quality,reduced symptom severity, and increased physical function. Side effects were negligible, with only one study reporting a very low incidence of mild and transient gastrointestinal symptoms.Click here to read more.
(2019/08) Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study.
(2019/06) Role of a natural integrator based on lipoic acid, palmitoiletanolamide and myrrh in the treatment of chronic pelvic pain and endometriosis.
(2017/04) Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: a meta-analysis.
(2011/05) Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study.
(2017/05) Role for a water-soluble form of CoQ10 in female subjects affected by fibromyalgia. A preliminary study.
(2013/04) Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?
(2009/05) Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia.
(2002/03) An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome.
(2017/05) Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT).
(2016/11) Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study.
(2015/01) Chondroitin for osteoarthritis.
(2013/03) Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence?
(2011/11) Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center.
(2011/06) Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
(2010/06) Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration.
(2010/06) Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study
(2009/02) Long-Term Effects of Chondroitins 4 and 6 Sulfate on Knee Osteoarthritis
(2008/09) Potential effects of chondroitin sulfate on joint swelling: a GAIT report.
(2007/01) Symptom and Structure Modifying Properties of Chondroitin Sulfate in Osteoarthritis
(2005/03) Chondroitins 4 and 6 Sulfate in Osteoarthritis of the Knee
(2016/10) Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative.
(2016/01) Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
(2015/11) Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee.
(2013/12) Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis.
(2010/09) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.
(2010/03) The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
(2010/01) Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis.
(2009/11) The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation.
(2009/01) A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis
(2008/10) The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.
(2006/02) Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis
(2006/02) Nutritional Supplements for Knee Osteoarthritis - Still No Resolution
(2003/07) Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis.
(2023/02) Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.
(2021/02) The Effect of a Dispersible Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Joint Pain in an Adult Population – A Randomised, Double-Blind Study.
(2017/07) Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.